Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. bronchomycn

Bronchomycn

First in class epithelial Barrier-enhancing medicine for respiratory diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Bronchomycn project word cloud

Explore the words cloud of the Bronchomycn project. It provides you a very rough idea of what is the project "Bronchomycn" about.

2    barriolides    27    rodents    accounted    membrane    epithelium    azithromycin    barrier    obstructive    investment    compounds    200    2014    usa    structurally    caused    ipr    stem    protection    turnover    49    airway    respiratory    hospital    2015    antibiotic    invested    class    stages    decreasing    14    2021    12    valued    bronchomycn    2004    organization    lacks    billion    prepare    regulatory    university    2022    points    morbidity    roi    people    ebf    market    efficient    agents    burden    ready    chronic    29    toxins    24    permeability    save    forecast    epiendo    807    mill    plan    copd    decided    treatment    28    medical    speed    23    acts    give    pulmonary    sales    considering    epithelial    near    consequence    belong    world    clinical    drugs    suffered    preclinical    2018    disorder    respectively    therapeutics    health    2026    cell    disease    economic    commercialization    48    vivo    million    deaths    64    drug    complications    2024    commercializing    continue    start    additional    infectious   

Project "Bronchomycn" data sheet

The following table provides information about the project.

Coordinator		 EPI-ENDO PHARMACEUTICALS EHF 

Organization address
address: 28 BORGARTUNI
city: REYKJAVIK
postcode: 105
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Iceland [IS]
 Project website http://www.epiendo.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EPI-ENDO PHARMACEUTICALS EHF IS (REYKJAVIK) coordinator 50˙000.00

Map

 Project objective

Chronic obstructive pulmonary disease (COPD) is a respiratory disorder that presents airway epithelial barrier failure (EBF) for which there are no efficient drugs, being a leading cause of chronic morbidity.

According to the World Health Organization 64 million people suffered COPD in 2004. The EU-28 and USA accounted for 23 and 12.7 million people respectively, which caused near 200,000 deaths. As a consequence of the medical complications of COPD the economic burden has been estimated as € 48.4 and € 29.3 billion in EU-28 and USA respectively

EpiEndo, aims at commercializing a new drug which will be able to save € 27 billion to EU-28 and USA.

Bronchomycn belong to Barriolides, a new class of compounds that provide effective treatment against EBF. Bronchomycn is structurally based on the well-known azithromycin, but lacks antibiotic activity and it acts by decreasing the permeability of the pulmonary epithelium membrane to toxins and infectious agents.

We have been working since 2014 in collaboration with the Stem Cell Research Unit and the University Hospital and now our product is in the early in-vivo stages, for what we have invested € 0.5 Mill. In order to get Bronchomycn to the market, we will start the Clinical studies in 2018 and we expect that current knowledge about side effects of azithromycin speed up the process so that the product will be ready for commercialization in 2021.

During Phase 1 we will prepare the preclinical studies in rodents and clinical studies and defining end-points and regulatory requirements, prepare IPR protection plan, etc.

The market for Bronchomycn is the respiratory therapeutics market which was valued at € 24.8 billion in 2015. We plan to start our sales in Europe in 2022 and USA in 2024, so that by 2026 our turnover will reach €807 Mill.

Therefore, we have decided to continue with Bronchomycn for what we need an additional investment of € 49 Mill, that considering a 5-years forecast will give us a ROI of 14.2

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRONCHOMYCN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRONCHOMYCN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More